Randomised controlled trial of Tumour necrosis factor inhibitors Against Combination Intensive Therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Controlled Trial ◽

Intensive Therapy ◽

Disease Modifying ◽

Randomised Controlled ◽

Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial

BMJ ◽

10.1136/bmj.h1046 ◽

2015 ◽

Vol 350 (mar13 19) ◽

pp. h1046-h1046 ◽

Cited By ~ 38

Author(s):

D. L. Scott ◽

F. Ibrahim ◽

V. Farewell ◽

A. G. O'Keeffe ◽

D. Walker ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Controlled Trial ◽

Intensive Therapy ◽

Disease Modifying ◽

Randomised Controlled ◽

The 'Switch’ study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug

BMC Musculoskeletal Disorders ◽

10.1186/1471-2474-15-452 ◽

2014 ◽

Vol 15 (1) ◽

Cited By ~ 15

Author(s):

Nuria C Navarro Coy ◽

Sarah Brown ◽

Ailsa Bosworth ◽

Claire T Davies ◽

Paul Emery ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Controlled Trial ◽

Tnf Inhibitor ◽

Inhibitor Drug ◽

Randomised Controlled ◽

Necrosis Factor ◽

Switch Study

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease

The Lancet ◽

10.1016/s0140-6736(97)80083-9 ◽

1997 ◽

Vol 349 (9051) ◽

pp. 521-524 ◽

Cited By ~ 279

Author(s):

WA Stack ◽

SD Mann ◽

AJ Roy ◽

P Heath ◽

M Sopwith ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Controlled Trial ◽

Tumour Necrosis Factor Α ◽

Randomised Controlled ◽

Factor Α ◽

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(21)00298-3 ◽

2021 ◽

Author(s):

Laurent Peyrin-Biroulet ◽

Ailsa Hart ◽

Peter Bossuyt ◽

Millie Long ◽

Matthieu Allez ◽

...

Keyword(s):

Ulcerative Colitis ◽

Maintenance Therapy ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Controlled Trial ◽

Phase 3 ◽

Previously Treated ◽

Randomised Controlled ◽

A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs

Annals of the Rheumatic Diseases ◽

10.1136/ard.2004.030908 ◽

2005 ◽

Vol 64 (9) ◽

pp. 1288-1293 ◽

Cited By ~ 44

Author(s):

E H Choy

Keyword(s):

Rheumatoid Arthritis ◽

Controlled Trial ◽

Disease Modifying Antirheumatic Drugs ◽

Antirheumatic Drugs ◽

Incomplete Response ◽

Disease Modifying ◽

Randomised Controlled

Immediate treatment with tumour necrosis factor inhibitors in synthetic disease-modifying anti-rheumatic drugs-naïve patients with rheumatoid arthritis: results of a modified Italian Expert Consensus

Rheumatology ◽

10.1093/rheumatology/key076 ◽

2018 ◽

Vol 57 (Supplement_7) ◽

pp. vii32-vii41

Author(s):

Alessandra Bortoluzzi ◽

Guido Valesini ◽

Salvatore D’Angelo ◽

Bruno Frediani ◽

Laura Bazzichi ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Expert Consensus ◽

Tumour Necrosis Factor Inhibitors ◽

Disease Modifying ◽

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

The Lancet ◽

10.1016/s0140-6736(16)00380-9 ◽

2016 ◽

Vol 388 (10041) ◽

pp. 239-247 ◽

Cited By ~ 65

Author(s):

Duncan Porter ◽

Jurgen van Melckebeke ◽

James Dale ◽

C Martina Messow ◽

Alexander McConnachie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Biological Treatment ◽

Open Label ◽

Randomised Controlled ◽

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

Annals of the Rheumatic Diseases ◽

10.1136/ard.2010.132134 ◽

2010 ◽

Vol 70 (2) ◽

pp. 266-271 ◽

Cited By ~ 91

Author(s):

C. Salliot ◽

A. Finckh ◽

W. Katchamart ◽

Y. Lu ◽

Y. Sun ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Meta Analysis ◽

Inadequate Response ◽

Disease Modifying Antirheumatic Drugs ◽

Antirheumatic Drugs ◽

Disease Modifying ◽

Indirect Comparisons ◽

Randomised double blind trial of safety of anti-tumour necrosis factor (anti-TNF) chimeric monoclonal antibody (infliximab) in combination with methatrexate compared to methatrexate alone in patients with rheumatoid arthritis on standard disease modifying anti-rheumatic drugs

http://isrctn.org/> ◽

10.1186/isrctn51200229 ◽

2013 ◽

Author(s):

Simon Till

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial ◽

Chimeric Monoclonal Antibody ◽

Disease Modifying ◽

THU0136 Long Term Outcomes of Stopping Tumour Necrosis Factor Inhibitors (TNFI) in Patients with Established Rheumatoid Arthritis (RA) Who are in Sustained Remission: Is it Worth the Risk?

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2013-eular.664 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A208.3-A209 ◽

Cited By ~ 4

Author(s):

C. Rakieh ◽

B. Saleem ◽

K. Takase ◽

J. L. Nam ◽

H. Keen ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Sustained Remission ◽

Long Term Outcomes ◽

Tumour Necrosis Factor Inhibitors ◽